Why were the results of the Heart Outcomes Prevention Evaluation ( HOPE ) trial so astounding ? 
<br>
<br> The Heart Outcomes Prevention Evaluation ( HOPE ) study was important because it showed the benefits of ramipril - an angiotensin - converting enzyme ( ACE ) inhibitor - in patients at high risk for cardiovascular events . Treatment with ramipril significantly reduced the <font color="red">rates_1</font> <font color="red">of_1</font> <font color="red">death_1</font> <font color="red">,_1</font> <font color="red">myocardial_1</font> <font color="red">infarction_1</font> <font color="red">,_1</font> <font color="red">stroke_1</font> <font color="red">,_1</font> <font color="red">coronary_1</font> <font color="red">revascularization_1</font> <font color="red">,_1</font> <font color="red">cardiac_1</font> <font color="red">arrest_1</font> <font color="red">and_1</font> <font color="red">heart_1</font> <font color="red">failure_1</font> <font color="red">,_1</font> as well as the <font color="red">risk_1</font> <font color="red">of_1</font> <font color="red">diabetes_1</font> <font color="red">-_1</font> <font color="red">related_1</font> <font color="red">complications_1</font> and of <font color="red">diabetes_1</font> itself . The effects of therapy with vitamin E were also evaluated , but no statistical benefits were shown . The benefits of ACE inhibitor therapy that were observed were likely due to a variety of mechanisms , not just a reduction in <font color="red">blood_1</font> <font color="red">pressure_1</font> <font color="red">._1</font>